
Above expectations
Teva Reports Revenue of $4.4 Billion
Adjusted gross profit margin soared to a decade high of 58.7% • The company raised its annual revenue forecast following sharp growth in innovative medicines
Person
Richard Francis — The CEO of Teva Pharmaceutical Industries Ltd since January 2023. Every TV10 Global story that covers or mentions Richard Francis, translated into English from TV10's Hebrew reporting.
2 stories on TV10 Global

Adjusted gross profit margin soared to a decade high of 58.7% • The company raised its annual revenue forecast following sharp growth in innovative medicines

Teva received approval from the U.S. Food and Drug Administration to market WELTRUZA, intended for adults • The new treatment is based on the active ingredient olanzapine and is administered as a once-monthly subcutaneous injection without the need for loading doses • The drug is expected to be available in the United States in the coming weeks